Grants per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MBA, Tufts University School of Medicine
… → 2001
Medicine, MD, Tufts University School of Medicine
… → 2001
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Prot#RPC01-3201: INDUCTION STUDY #1- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Cro
Hanauer, S. B. (PD/PI) & Yen, E. F. (PD/PI)
ICON Clinical Research, LLC, Celgene International II Sàrl
9/9/19 → 9/9/25
Project: Research project
-
Prot#RPC01-3203: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease”
Hanauer, S. B. (PD/PI) & Yen, E. F. (PD/PI)
ICON Clinical Research, LLC, Celgene International II Sàrl
9/9/19 → 4/18/25
Project: Research project
-
Prot# RPC01-3204: A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Serverely Active Crohn's Disease
Hanauer, S. B. (PD/PI) & Yen, E. F. (PD/PI)
ICON Clinical Research, LLC, Celgene International II Sàrl
9/9/19 → 3/31/25
Project: Research project
-
Development of an Entrustable Professional Activity for Intestinal Ultrasound in North America
the Intestinal Ultrasound Group of the United States and Canada (iUSCAN) Education Committee, 2025, (Accepted/In press) In: American Journal of Gastroenterology. 10.14309/ajg.0000000000003435.Research output: Contribution to journal › Article › peer-review
-
Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial
Allegretti, J. R., Kelly, C. R., Louie, T., Fischer, M., Hota, S., Misra, B., Van Hise, N. W., Yen, E., Bullock, J. S., Silverman, M., Davis, I., McGill, S. K., Pardi, D. S., Orenstein, R., Grinspan, A., El-Nachef, N., Feuerstadt, P., Borody, T. J., Khanna, S. & Budree, S. & 1 others, , Feb 2025, In: Gastroenterology. 168, 2, p. 357-366.e3Research output: Contribution to journal › Article › peer-review
6 Scopus citations -
The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program †
Hanauer, S. B., Torres, E. A., Aragon-Han, P., Chapman, J. C., Swaminath, A. C., Arai, R., Butnariu, M., Lee, T. C., Rabizadeh, S., Check, M., Barrett, T. A., Hashash, J. G., Meister, T., Yen, E. F., Kinnucan, J., Stein, D. J., Ziring, D., Shaposhnikov, R., Sinh, P. & Qazi, T. M. & 4 others, , Apr 2025, In: Pharmaceutics. 17, 4, 428.Research output: Contribution to journal › Article › peer-review
-
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI (Infectious Diseases and Therapy, (2024), 13, 10, (2105-2121), 10.1007/s40121-024-01007-z)
on behalf of the ECOSPOR III and ECOSPOR IV investigators, Oct 2024, In: Infectious Diseases and Therapy. 13, 10, p. 2209-2210 2 p.Research output: Contribution to journal › Comment/debate › peer-review
-
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
on behalf of the ECOSPOR III and ECOSPOR IV investigators, Oct 2024, In: Infectious Diseases and Therapy. 13, 10, p. 2105-2121 17 p.Research output: Contribution to journal › Article › peer-review
Datasets
-
Nonsteroidal anti-inflammatory drug exposure and the risk of microscopic colitis
Yen, E. F. (Creator), Amusin, D. B. (Creator), Yoo, J. (Creator), Ture, A. (Creator), Gentile, N. M. (Creator), Goldberg, M. J. (Creator) & Goldstein, J. L. (Creator), figshare, 2022
DOI: 10.6084/m9.figshare.c.6125616.v1, https://springernature.figshare.com/collections/Nonsteroidal_anti-inflammatory_drug_exposure_and_the_risk_of_microscopic_colitis/6125616/1
Dataset